135 related articles for article (PubMed ID: 38412693)
1. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R
Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
[TBL] [Abstract][Full Text] [Related]
3. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
[TBL] [Abstract][Full Text] [Related]
4. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
5. A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro.
Allali-Hassani A; Kuznetsova E; Hajian T; Wu H; Dombrovski L; Li Y; Gräslund S; Arrowsmith CH; Schapira M; Vedadi M
J Biomol Screen; 2014 Jul; 19(6):928-35. PubMed ID: 24595546
[TBL] [Abstract][Full Text] [Related]
6. Identification of LEM-14 inhibitor of the oncoprotein NSD2.
Shen Y; Morishita M; Lee D; Kim S; Lee T; Mevius DEHF; Roh Y; di Luccio E
Biochem Biophys Res Commun; 2019 Jan; 508(1):102-108. PubMed ID: 30471851
[TBL] [Abstract][Full Text] [Related]
7. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
9. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Bennett RL; Swaroop A; Troche C; Licht JD
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
Sun Y; Zhang Y; Chen X; Yu A; Du W; Huang Y; Wu F; Yu L; Li J; Wen C; Yang H; Shi Q; Geng M; Huang X; Xu S
Eur J Med Chem; 2022 Sep; 239():114528. PubMed ID: 35717870
[TBL] [Abstract][Full Text] [Related]
11. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
He C; Li F; Zhang J; Wu J; Shi Y
J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
[TBL] [Abstract][Full Text] [Related]
13. Cancers and the NSD family of histone lysine methyltransferases.
Morishita M; di Luccio E
Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
[TBL] [Abstract][Full Text] [Related]
14. High yield recombinant expression and purification of oncogenic NSD1, NSD2, and NSD3 with human influenza hemagglutinin tag.
Shen Y; Morishita M; di Luccio E
Protein Expr Purif; 2020 Feb; 166():105506. PubMed ID: 31563542
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
Morishita M; di Luccio E
Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
[TBL] [Abstract][Full Text] [Related]
16. The NSD family of protein methyltransferases in human cancer.
Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.
di Luccio E
J Cancer Prev; 2015 Jun; 20(2):113-20. PubMed ID: 26151044
[TBL] [Abstract][Full Text] [Related]
18. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.
Poulin MB; Schneck JL; Matico RE; McDevitt PJ; Huddleston MJ; Hou W; Johnson NW; Thrall SH; Meek TD; Schramm VL
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1197-201. PubMed ID: 26787850
[TBL] [Abstract][Full Text] [Related]
19. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
Zhu L; Yu CL; Zheng Y
Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
[TBL] [Abstract][Full Text] [Related]
20. Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
Min W; Hou Z; Zhang F; Xie S; Yuan K; Dong H; Wang L; Qi L; Luo C; Ding H; Yang P
Bioorg Med Chem; 2020 Apr; 28(7):115372. PubMed ID: 32088124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]